Back to results
US 2022/0259591 A1Published application
Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
AssigneeNorthwestern University
InventorsWilliam A. Muller, Bita F. Cyrus
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for the inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C) expression and/or activity, and treatment or prevention of inflammation therewith.
Claims13
1-20. (canceled)
A method of inhibiting transendothelial migration (TEM) of leukocytes within a subject comprising administering to endothelial cells of the subject an effective amount of an agent comprising a peptide that competes with kinesin light chain 1, variant 1 (KLC1C) for binding to its cargo, wherein the peptide comprises a sequence of SEQ ID NO:
- 4 and a cell-penetrating peptide sequence.
Dependencies are inferred from the claim text.